Marie Surpris
Child & Adolescent Psychiatry · Nesconset, NYNPI 1295944981
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 137 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by AbbVie at 32.9% of the total. Reporting peaked in 2019 at $1,302 and has fallen 59.7% since, to $525 in 2023. Among child & adolescent psychiatry clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 137 payments — averaging $23.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Sunovion Pharmaceuticals Inc.$346
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$332
- Johnson & Johnson$273
- Takeda Pharmaceuticals U.S.A., Inc.$199
- Corium, LLC$149
- plus $890 from 12 others
What the payments were for
- Food & beverage$3,261100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 38 | $1,072 |
| Sunovion Pharmaceuticals Inc. | 21 | $346 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 14 | $332 |
| Johnson & Johnson | 4 | $273 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $199 |
| Corium, LLC | 6 | $149 |
| Alfasigma USA, Inc. | 7 | $140 |
| Supernus Pharmaceuticals, Inc. | 4 | $120 |
| Indivior Inc. | 1 | $118 |
| Arbor Pharmaceuticals, Inc. | 10 | $110 |
| Axsome Therapeutics, Inc. | 4 | $105 |
| Otsuka America Pharmaceutical, Inc. | 7 | $97 |
| Ironshore Pharmaceuticals Inc. | 3 | $56 |
| Shire North American Group Inc | 3 | $42 |
| Alkermes, Inc. | 2 | $35 |
| Tris Pharma Inc | 2 | $26 |
| Eisai Inc. | 1 | $23 |
| Vertical Pharmaceuticals, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,261 in reported general payments places this provider in the 90th percentile of 317 child & adolescent psychiatry providers in New York.
See all child & adolescent psychiatry providers in New York →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Vilazodone Hcl | 17 | $1,329 |
| Aripiprazole | 47 | $429 |
| Amitriptyline Hcl | 23 | $345 |
| Duloxetine Hcl | 15 | $270 |
| Quetiapine Fumarate | 14 | $252 |
| Lamotrigine | 14 | $152 |
| Clonazepam | 28 | $140 |
| Fluoxetine Hcl | 17 | $99 |
| Mirtazapine | 11 | $31 |
| Lithium Carbonate | 11 | $17 |
Paid to pharmacies, not to this prescriber.
Other child & adolescent psychiatry in Nesconset
- Matthew LorberNew York$398K
- Mitchell CabisudoNew Windsor$346K
- Parinda ParikhWhite Plains$185K
- Jeffrey NewcornNew York$165K
- John MarinoCanandaigua$70K
- Iliyan IvanovNew York$38K
- Melvin OatisNew York$35K
- Vijay PampanaMiddletown$19K
- Marc ReitmanHuntington$13K
- Marie CharlesBrooklyn$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.